Anatibant Mesilate

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAnatibant Mesilate
Drug Alias Name甲磺酸阿那替班anatibantum阿替班特甲磺酸盐阿那替班甲磺酸盐甲磺酸阿替班特 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBradykinin B2 receptor antagonists
TargetsBradykinin B2 receptor
Therapy Area/IndicationsBrain Injuries
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsBrain Injuries

Other Information

ATC CodeN/A
Related LinksDrugBank